Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Senate Finance Committee Turns Attention To Pfizer COX-2 Documents

This article was originally published in The Pink Sheet Daily

Executive Summary

The Senate Finance Committee is starting to review Pfizer documents on COX-2 inhibitors submitted in response to a December request

You may also be interested in...



Sen. Grassley's Proposed Drug Safety Office Would Have Labeling Authority

Finance Committee chairman is considering the feasibility of giving an independent drug safety office authority to suspend direct-to-consumer ads and marketing. The senator expects to offer legislation that would create the drug safety office soon, although the timeline may change based upon other legislators' actions.

Sen. Grassley's Proposed Drug Safety Office Would Have Labeling Authority

Finance Committee chairman is considering the feasibility of giving an independent drug safety office authority to suspend direct-to-consumer ads and marketing. The senator expects to offer legislation that would create the drug safety office soon, although the timeline may change based upon other legislators' actions.

Sen. Grassley Asks FDA, Pfizer To Detail Bextra Labeling Changes

The Senate Finance Committee request suggests there could be less flexibility in future label negotiations because of possible congressional scrutiny. Grassley also asks for briefings on Meridia, Crestor, Accutane and Serevent from FDA.

Topics

UsernamePublicRestriction

Register

ID001014

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel